Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
In this “Safety Speaks” conversation, CommonSpirit Health's Beth Miller, system director, patient safety-performance improvement, and Austin Peterson, system…
Headline
In this conversation, Oren Guttman, M.D., anesthesiologist and vice president of High Reliability & Patient Safety at Thomas Jefferson University,…
Headline
A new AHA case study highlights how Springfield Memorial Hospital in Illinois revised its patient safety culture through the implementation of its unique,…
Chairperson's File
In this episode, I talk with Steve Diaz, M.D., chief medical officer at MaineGeneral Health in Augusta and an AHA board member. Steve is an emergency medicine…
Headline
The AHA Sept. 26 launched a new video series in which former AHA Board Chair Mindy Estes, M.D., has conversations with hospital and health system leaders about…
Perspective
There will always be administrative costs associated with operating a hospital. But the lion’s share of a hospital’s resources should be devoted to doing what…